{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:45:32Z","timestamp":1792601132846,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.coph.2018.04.011","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T10:12:49Z","timestamp":1525860769000},"page":"134-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"special_numbering":"C","title":["Targeting WNT signaling in the treatment of osteoporosis"],"prefix":"10.1016","volume":"40","author":[{"given":"Roland","family":"Baron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2018.04.011_bib0005","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.coph.2018.04.011_bib0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1210\/jc.2011-2332","article-title":"Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives","volume":"97","author":"Baron","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2018.04.011_bib0015","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1359\/jbmr.070104","article-title":"Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium","volume":"22","author":"Lindsay","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.coph.2015.03.005","article-title":"Parathyroid hormone: anabolic and catabolic actions on the skeleton","volume":"22","author":"Silva","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.coph.2018.04.011_bib0025","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development","volume":"107","author":"Gong","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.coph.2018.04.011_bib0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/338450","article-title":"A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait","volume":"70","author":"Little","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.coph.2018.04.011_bib0035","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","article-title":"High bone density due to a mutation in LDL-receptor-related protein 5","volume":"346","author":"Boyden","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.04.011_bib0040","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","author":"van Bezooijen","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.coph.2018.04.011_bib0045","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1101\/gr.3437105","article-title":"Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease","volume":"15","author":"Loots","year":"2005","journal-title":"Genome Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease","volume":"39","author":"Balemans","year":"2002","journal-title":"J Med Genet"},{"key":"10.1016\/j.coph.2018.04.011_bib0055","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.coph.2018.04.011_bib0060","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/jbmr.3160","article-title":"The Lrp4R1170Q homozygous knock-in mouse recapitulates the bone phenotype of sclerosteosis in humans","volume":"32","author":"Boudin","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0065","doi-asserted-by":"crossref","first-page":"E5187","DOI":"10.1073\/pnas.1413828111","article-title":"Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels","volume":"111","author":"Chang","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2018.04.011_bib0070","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/jbmr.2782","article-title":"A novel domain-specific mutation in a sclerosteosis patient suggests a role of LRP4 as an anchor for sclerostin in human bone","volume":"31","author":"Fijalkowski","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0075","doi-asserted-by":"crossref","first-page":"19489","DOI":"10.1074\/jbc.M110.190330","article-title":"Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function","volume":"286","author":"Leupin","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2018.04.011_bib0080","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1359\/jbmr.060810","article-title":"Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity","volume":"21","author":"Ellies","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0085","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1359\/jbmr.060311","article-title":"Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass","volume":"21","author":"Morvan","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0090","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(08)60599-1","article-title":"Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study","volume":"371","author":"Richards","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2018.04.011_bib0095","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ng.2249","article-title":"Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture","volume":"44","author":"Estrada","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.coph.2018.04.011_bib0100","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1007\/s00198-013-2302-0","article-title":"Missense polymorphisms of the WNT16 gene are associated with bone mass, hip geometry and fractures","volume":"24","author":"Garcia-Ibarbia","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.coph.2018.04.011_bib0105","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2018.04.011_bib0110","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1002\/jcb.25179","article-title":"Genetic approaches to identifying novel osteoporosis drug targets","volume":"116","author":"Brommage","year":"2015","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.coph.2018.04.011_bib0115","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature14259","article-title":"Notum deacylates Wnt proteins to suppress signalling activity","volume":"519","author":"Kakugawa","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.coph.2018.04.011_bib0120","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","article-title":"Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation","volume":"8","author":"Glass","year":"2005","journal-title":"Dev Cell"},{"key":"10.1016\/j.coph.2018.04.011_bib0125","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1128\/MCB.01428-09","article-title":"Osteocyte Wnt\/beta-catenin signaling is required for normal bone homeostasis","volume":"30","author":"Kramer","year":"2010","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.coph.2018.04.011_bib0130","doi-asserted-by":"crossref","first-page":"21162","DOI":"10.1074\/jbc.M501900200","article-title":"Essential role of beta-catenin in postnatal bone acquisition","volume":"280","author":"Holmen","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2018.04.011_bib0135","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1128\/MCB.05980-11","article-title":"Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin","volume":"31","author":"Wei","year":"2011","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.coph.2018.04.011_bib0140","series-title":"Osteoporosis","first-page":"411","article-title":"Wnt signaling in skeletal homeostasis and diseases","author":"Gori","year":"2013"},{"key":"10.1016\/j.coph.2018.04.011_bib0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/beta-catenin signaling: components, mechanisms, and diseases","volume":"17","author":"MacDonald","year":"2009","journal-title":"Dev Cell"},{"key":"10.1016\/j.coph.2018.04.011_bib0150","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ctrv.2017.11.002","article-title":"Targeting the Wnt\/beta-catenin pathway in cancer: update on effectors and inhibitors","volume":"62","author":"Krishnamurthy","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.coph.2018.04.011_bib0155","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.coph.2018.04.011_bib0160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-3-319-04843-7_2","article-title":"Wnt signaling in osteosarcoma","volume":"804","author":"Lin","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.coph.2018.04.011_bib0165","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jbmr.320","article-title":"The amazing osteocyte","volume":"26","author":"Bonewald","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0170","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coph.2016.02.003","article-title":"Osteocytes: the master cells in bone remodelling","volume":"28","author":"Prideaux","year":"2016","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.coph.2018.04.011_bib0175","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.coph.2018.04.011_bib0180","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin","volume":"283","author":"Robling","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2018.04.011_bib0185","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1210\/jc.2005-1235","article-title":"Bone mineral density in sclerosteosis; affected individuals and gene carriers","volume":"90","author":"Gardner","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2018.04.011_bib0190","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J"},{"key":"10.1016\/j.coph.2018.04.011_bib0195","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem"},{"issue":"Suppl. 1","key":"10.1016\/j.coph.2018.04.011_bib0200","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2106\/JBJS.G.01183","article-title":"Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling","volume":"90","author":"ten Dijke","year":"2008","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.coph.2018.04.011_bib0205","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/nm.2452","article-title":"Evidence for osteocyte regulation of bone homeostasis through RANKL expression","volume":"17","author":"Nakashima","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2018.04.011_bib0210","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/nm.2448","article-title":"Matrix-embedded cells control osteoclast formation","volume":"17","author":"Xiong","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2018.04.011_bib0215","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0220","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bone.2010.09.009","article-title":"Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model","volume":"48","author":"Tian","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.coph.2018.04.011_bib0225","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0230","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/jbmr.182","article-title":"Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats","volume":"25","author":"Li","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0235","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bone.2016.10.018","article-title":"Application of anti-Sclerostin therapy in non-osteoporosis disease models","volume":"96","author":"Jacobsen","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.coph.2018.04.011_bib0240","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0245","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jbmr.2152","article-title":"Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody","volume":"29","author":"Ominsky","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0250","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/jbmr.3036","article-title":"Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys","volume":"32","author":"Ominsky","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0255","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jbmr.3038","article-title":"Sclerostin antibody administration converts bone lining cells into active osteoblasts","volume":"32","author":"Kim","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0260","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2015.12.013","article-title":"Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats","volume":"84","author":"Taylor","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.coph.2018.04.011_bib0265","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bone.2015.08.007","article-title":"Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats","volume":"81","author":"Ominsky","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.coph.2018.04.011_bib0270","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1172\/JCI91699","article-title":"Parathyroid hormone regulates fates of murine osteoblast precursors in vivo","volume":"127","author":"Balani","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2018.04.011_bib0275","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s00774-015-0707-x","article-title":"Intermittent PTH treatment can delay the transformation of mature osteoblasts into lining cells on the periosteal surfaces","volume":"34","author":"Jang","year":"2016","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.coph.2018.04.011_bib0280","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/jcb.21626","article-title":"PTH\/cAMP\/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells","volume":"104","author":"Suzuki","year":"2008","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.coph.2018.04.011_bib0285","doi-asserted-by":"crossref","first-page":"14756","DOI":"10.1074\/jbc.M110.102970","article-title":"Parathyroid hormone receptor directly interacts with dishevelled to regulate beta-Catenin signaling and osteoclastogenesis","volume":"285","author":"Romero","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2018.04.011_bib0290","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1210\/en.2005-1627","article-title":"Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells","volume":"147","author":"Tobimatsu","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.coph.2018.04.011_bib0295","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1101\/gad.1702708","article-title":"Parathyroid hormone signaling through low-density lipoprotein-related protein 6","volume":"22","author":"Wan","year":"2008","journal-title":"Genes Dev"},{"key":"10.1016\/j.coph.2018.04.011_bib0300","doi-asserted-by":"crossref","first-page":"e2942","DOI":"10.1371\/journal.pone.0002942","article-title":"Control of bone mass and remodeling by PTH receptor signaling in osteocytes","volume":"3","author":"O\u2019Brien","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coph.2018.04.011_bib0305","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/jbmr.1492","article-title":"Mef2c deletion in osteocytes results in increased bone mass","volume":"27","author":"Kramer","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0310","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cmet.2009.12.007","article-title":"Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation","volume":"11","author":"Guo","year":"2010","journal-title":"Cell Metab"},{"key":"10.1016\/j.coph.2018.04.011_bib0315","doi-asserted-by":"crossref","first-page":"13176","DOI":"10.1038\/ncomms13176","article-title":"SIKs control osteocyte responses to parathyroid hormone","volume":"7","author":"Wein","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2018.04.011_bib0320","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031237","article-title":"Regulation of bone remodeling by parathyroid hormone","author":"Wein","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.coph.2018.04.011_bib0325","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0330","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jbmr.2092","article-title":"Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women","volume":"29","author":"McColm","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0335","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.04.011_bib0340","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0345","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/jbmr.474","article-title":"Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover","volume":"26","author":"van Lierop","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0350","doi-asserted-by":"crossref","first-page":"E252","DOI":"10.1210\/jc.2013-3278","article-title":"Serum Dickkopf 1 levels in sclerostin deficiency","volume":"99","author":"van Lierop","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2018.04.011_bib0355","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.04.011_bib0360","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.04.011_bib0365","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1056\/NEJMc1402396","article-title":"Romosozumab in postmenopausal women with osteopenia","volume":"370","author":"Evenepoel","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.04.011_bib0370","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1161\/CIRCRESAHA.110.234278","article-title":"The regulation of valvular and vascular sclerosis by osteogenic morphogens","volume":"109","author":"Bostrom","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.coph.2018.04.011_bib0375","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bone.2013.05.010","article-title":"The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women","volume":"56","author":"Hampson","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.coph.2018.04.011_bib0380","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/jbmr.1794","article-title":"Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers","volume":"28","author":"van Lierop","year":"2013","journal-title":"J Bone Miner Res"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218300201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218300201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T22:21:11Z","timestamp":1534890071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489218300201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":76,"alternative-id":["S1471489218300201"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2018.04.011","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting WNT signaling in the treatment of osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2018.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}